Allergan stock soars on deal rumors

Wall Street is abuzz today with talk that Allergan may be on the block. Options traders have snapped up 13,000 April contracts--yep, that's 13,000, way beyond the normal volume. Apparently, they were set in motion by a web report that GlaxoSmithKline might be interested in the Botox-maker.

At press time, Allergan stock was up around 10 percent to over $47--after leaping by 13 percent earlier in the day, exceeding its 50-day moving average. Drug stocks in general were up, so some of Allergan's rise could be overall market pressure. And it's true that some analysts have tagged Allergan as a buy lately. And Fast Money yesterday recommended an Allergan buy for first thing today.

But professional traders are the options-buyers that swooped in for those thousands of contracts--and that's not a standard-issue up-market move. So what's going on? GSK won't comment, and Allergan won't either.

- see the story at Option Monster
- get more from The Street
- read the brief at MarketWatch

Suggested Articles

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Novartis hopes to leverage its existing presence in the hematology community to achieve a successful launch of Adakveo.

AstraZeneca's Farxiga is touting its heart failure data in patients with or without diabetes, but results in non-diabetics looks particularly strong.